Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
CONTEXT: Various drugs affect body weight as a side effect. OBJECTIVE: We conducted this systematic review and meta-analysis to summarize the evidence about commonly prescribed drugs and their association with weight change. DATA SOURCES: MEDLINE, DARE, and the Cochrane Database of Systematic Reviews were searched to identify published systematic reviews as a source for trials. STUDY SELECTION: We included randomized trials that compared an a priori selected list of drugs to placebo and measured weight change. DATA EXTRACTION: We extracted data in duplicate and assessed the methodological quality using the Cochrane risk of bias tool. RESULTS: We included 257 randomized trials (54 different drugs; 84 696 patients enrolled). Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperidone (0.8 kg), gabapentin (2.2 kg), tolbutamide (2.8 kg), pioglitazone (2.6 kg), glimepiride (2.1 kg), gliclazide (1.8 kg), glyburide (2.6 kg), glipizide (2.2 kg), sitagliptin (0.55 kg), and nateglinide (0.3 kg). Weight loss was associated with the use of metformin (1.1 kg), acarbose (0.4 kg), miglitol (0.7 kg), pramlintide (2.3 kg), liraglutide (1.7 kg), exenatide (1.2 kg), zonisamide (7.7 kg), topiramate (3.8 kg), bupropion (1.3 kg), and fluoxetine (1.3 kg). For many other remaining drugs (including antihypertensives and antihistamines), the weight change was either statistically nonsignificant or supported by very low-quality evidence. CONCLUSIONS: Several drugs are associated with weight change of varying magnitude. Data are provided to guide the choice of drug when several options exist and institute preemptive weight loss strategies when obesogenic drugs are prescribed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
“Our Task Force adopted these cutpoints, realizing that they are arbitrary and only low-quality evidence supports associations determined by these cutpoints.”
InfluentialSelf-citationObesity in children and adolescents: epidemiology, causes, assessment, and management
Jebeile, H., Kelly, A. S., O'Malley, G., & Baur, L. A. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00047-x · Cited by 1,099
Comorbid depression in medical diseases
Gold, S. M., Köhler-Forsberg, O., Moss-Morris, R., Mehnert, A., Miranda, J. J., Bullinger, M., Steptoe, A., Whooley, M. A., & Otte, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0200-2 · Cited by 534
ESPEN guidelines on nutrition in dementia
Volkert, D., Chourdakis, M., Faxen-Irving, G., Frühwald, T., Landi, F., Suominen, M. H., Vandewoude, M., Wirth, R., & Schneider, S. M. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2015.09.004 · Cited by 442
Berk, M., Köhler‐Forsberg, O., Turner, M., Penninx, B. W. J. H., Wrobel, A., Firth, J., Loughman, A., Reavley, N. J., McGrath, J. J., Momen, N. C., et al. (2023) · World Psychiatry · doi:10.1002/wps.21110 · Cited by 336
Anti-Obesity Activity of the Marine Carotenoid Fucoxanthin
Gammone, M., & D'Orazio, N. (2015) · Marine Drugs · doi:10.3390/md13042196 · Cited by 321
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s008 · Cited by 244
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s008 · Cited by 244
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s008 · Cited by 236
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s008 · Cited by 213
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s008 · Cited by 158
Apolzan, J. W., Venditti, E. M., Edelstein, S. L., Knowler, W. C., Dabelea, D., Boyko, E. J., Pi-Sunyer, X., Kalyani, R. R., Franks, P. W., Srikanthan, P., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-1605 · Cited by 156
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Tokubuchi, I., Tajiri, Y., Iwata, S., Hara, K., Wada, N., Hashinaga, T., Nakayama, H., Mifune, H., & Yamada, K. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171293 · Cited by 121
Medications that cause weight gain and alternatives in Canada: a narrative review
Wharton, S., Raiber, L., Serodio, K., Lee, J., & Christensen, R. A. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s171365 · Cited by 100
“4 kg.(5,91,102) Additional information on the use of liraglutide 3.”
BackgroundInteractions between Food and Drugs, and Nutritional Status in Renal Patients: A Narrative Review
D’Alessandro, C., Benedetti, A., Di Paolo, A., Giannese, D., & Cupisti, A. (2022) · Nutrients · doi:10.3390/nu14010212 · Cited by 66
The new era of drug therapy for obesity: the evidence and the expectations
Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58
Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder
Grootens, K. P., Meijer, A., Hartong, E. G., Doornbos, B., Bakker, P. R., Al Hadithy, A., Hoogerheide, K. N., Overmeire, F., Marijnissen, R. M., & Ruhe, H. G. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2517-2 · Cited by 60
Verhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53
“In patients who are obese or those with diabetes, GLP-1 RA demonstrates long-lasting weight loss and benefits on glucose metabolism [1, 3].”
BackgroundInfluentialMetformin: an old therapy that deserves a new indication for the treatment of obesity.
Igel, L. I., Sinha, A., Saunders, K. H., Apovian, C. M., Vojta, D., & Aronne, L. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0568-3 · Cited by 52
Effect of Obesogenic Medications on Weight‐Loss Outcomes in a Behavioral Weight‐Management Program
Desalermos, A., Russell, B., Leggett, C., Parnell, A., Ober, K., Hagerich, K., Gerlan, C., Ganji, G., Lee, E., Proudfoot, J. A., et al. (2019) · Obesity · doi:10.1002/oby.22444 · Cited by 47
Ptomey, L. T., Saunders, R. R., Saunders, M., Washburn, R. A., Mayo, M. S., Sullivan, D. K., Gibson, C. A., Goetz, J. R., Honas, J. J., Willis, E. A., et al. (2018) · Journal of Applied Research in Intellectual Disabilities · doi:10.1111/jar.12348 · Cited by 47
Burnatowska, E., Wikarek, A., Oboza, P., Ogarek, N., Glinianowicz, M., Kocelak, P., & Olszanecka-Glinianowicz, M. (2023) · Nutrients · doi:10.3390/nu15020295 · Cited by 44
“A systemic review and meta-analysis of randomized trials showed a lack of efficacy of metformin in obesity treatment [70].”
BackgroundEpidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
“3-kg average weight loss, and all other SSRIs appear weight neutral.(163) If a temporal association exists between weight gain and initiation of SSRIs, consideration could be given to their replacement.”
BackgroundGao, L., Huang, H., Zhang, L., Zhang, N., Fu, Y., Zhu, D., Bi, Y., & Feng, W. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1608-0345 · Cited by 24
“Based on previous studies [10, 22], GLP1RAs and metformin decreased body weight by around 3.”
Lyu, B., Chang, A. R., Inker, L. A., Selvin, E., Grams, M. E., & Shin, J.-I. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100249 · Cited by 22
Giusti, L., Bianchini, V., Aggio, A., Mammarella, S., Salza, A., Necozione, S., Alunno, A., Ferri, C., Casacchia, M., & Roncone, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.903759 · Cited by 6
Metadata
- Authors
- Domecq, J. P., Prutsky, G., Leppin, A., Sonbol, M. B., Altayar, O., Undavalli, C., Wang, Z., Elraiyah, T., Brito, J. P., Mauck, K. F., Lababidi, M. H., Prokop, L. J., Asi, N., Wei, J., Fidahussein, S., Montori, V. M., & Murad, M. H.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 363-370
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2014735081
- Cited by
- 334
- References
- 51
- FWCI
- 21.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.